Multidimensional Early Prediction Score for Drug-Resistant Epilepsy

다국어 초록 (Multilingual Abstract)

Background and Purpose Achieving favorable postoperative outcomes in patients with drug-resistant epilepsy (DRE) requires early referrals for preoperative examinations. The purpose of this study was to investigate the possibility of a user-friendly early DRE prediction model that is easy for nonexperts to utilize.
Methods A two-step genotype analysis was performed, by applying 1) whole-exome sequencing (WES) to the initial test set (n=243) and 2) target sequencing to the validation set (n=311).
Based on a multicenter case–control study design using the WES data set, 11 genetic and 2 clinical predictors were selected to develop the DRE risk prediction model. The early prediction scores for DRE (EPS-DRE) was calculated for each group of the selected genetic predictors (EPS-DREgen), clinical predictors (EPS-DREcln), and two types of predictor mix (EPS-DREmix) in both the initial test set and the validation set.
Results The multidimensional EPS-DREmix of the predictor mix group provided a better match to the outcome data than did the unidimensional EPS-DREgen or EPS-DREcln. Unlike previous studies, the EPS-DREmix model was developed using only 11 genetic and 2 clinical predictors, but it exhibited good discrimination ability in distinguishing DRE from drug-responsive epilepsy. These results were verified using an unrelated validation set.
Conclusions Our results suggest that EPS-DREmix has good performance in early DRE prediction and is a user-friendly tool that is easy to apply in real clinical trials, especially by nonexperts who do not have detailed knowledge or equipment for assessing DRE. Further studies are needed to improve the performance of the EPS-DREmix model.

참고문헌 (Reference)

1 Berg AT, "Understanding the delay before epilepsy surgery : who develops intractable focal epilepsy and when?" 9 : 136-144, 2004

2 Choi SW, "Tutorial : a guide to performing polygenic risk score analyses" 15 : 2759-2772, 2020

3 Chen Z, "Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs : a 30-year longitudinal cohort study" 75 : 279-286, 2018

4 Engel J Jr, "The timing of surgical intervention for mesial temporal lobe epilepsy : a plan for a randomized clinical trial" 56 : 1338-1341, 1999

5 Fuchsberger C, "The genetic architecture of type 2 diabetes" 536 : 41-47, 2016

6 Kalilani L, "The epidemiology of drug-resistant epilepsy : a systematic review and metaanalysis" 59 : 2179-2193, 2018

7 Dlugos DJ, "The early identification of candidates for epilepsy surgery" 58 : 1543-1546, 2001

8 Begley CE, "The direct cost of epilepsy in the United States : a systematic review of estimates" 56 : 1376-1387, 2015

9 Perry MS, "Surgical versus medical treatment for refractory epilepsy : outcomes beyond seizure control" 54 : 2060-2070, 2013

10 Dwivedi R, "Surgery for drug-resistant epilepsy in children" 377 : 1639-1647, 2017

11 Zhang Z, "Somatic variants in new candidate genes identified in focal cortical dysplasia type II" 61 : 667-678, 2020

12 Meguins LC, "Shorter epilepsy duration is associated with better seizure outcome in temporal lobe epilepsy surgery" 73 : 212-217, 2015

13 Lascano AM, "Seizures and epilepsies due to channelopathies and neurotransmitter receptor dysfunction : a parallel between genetic and immune aspects" 7 : 197-209, 2016

14 Haneef Z, "Referral pattern for epilepsy surgery after evidence-based recommendations : a retrospective study" 75 : 699-704, 2010

15 Gibson G, "Rare and common variants : twenty arguments" 13 : 135-145, 2012

16 Fiest KM, "Prevalence and incidence of epilepsy : a systematic review and metaanalysis of international studies" 88 : 296-303, 2017

17 Jeha LE, "Predictors of outcome after temporal lobectomy for the treatment of intractable epilepsy" 66 : 1938-1940, 2006

18 Engel J Jr, "Practice parameter : temporal lobe and localized neocortical resections for epilepsy : report of the Quality Standards Subcommittee of the American Academy of Neurology, in association with the American Epilepsy Society and the American Association of Neurological Surgeons" 60 : 538-547, 2003

19 Mavaddat N, "Polygenic risk scores for prediction of breast cancer and breast cancer subtypes" 104 : 21-34, 2019

20 Gilliam F, "Patient-oriented outcome assessment after temporal lobectomy for refractory epilepsy" 53 : 687-694, 1999

21 Mohanraj R, "Mortality in adults with newly diagnosed and chronic epilepsy : a retrospective comparative study" 5 : 481-487, 2006

22 Sisodiya SM, "Mechanisms of antiepileptic drug resistance" 16 : 197-201, 2003

23 Golan D, "Measuring missing heritability : inferring the contribution of common variants" 111 : E5272-E5281, 2014

24 Rudolph A, "Joint associations of a polygenic risk score and environmental risk factors for breast cancer in the Breast Cancer Association Consortium" 47 : 526-536, 2018

25 Lawn ND, "Injuries due to seizures in persons with epilepsy : a population-based study" 63 : 1565-1570, 2004

26 Spencer SS, "Initial outcomes in the multicenter study of epilepsy surgery" 61 : 1680-1685, 2003

27 Martin AR, "Human demographic history impacts genetic risk prediction across diverse populations" 100 : 635-649, 2017

28 Berg AT, "How long does it take for partial epilepsy to become intractable?" 60 : 186-190, 2003

29 Khera AV, "Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations" 50 : 1219-1224, 2018

30 Kang KW, "Genetic characteristics of non-familial epilepsy" 7 : e8278-, 2019

31 고아라 ; Joon Soo Lee, "Factors associated with seizure and cognitive outcomes after epilepsy surgery for low-grade epilepsy-associated neuroepithelial tumors in children" 대한소아청소년과학회 63 (63): 171-177, 2020

32 Choi H, "Evaluation of duration of epilepsy prior to temporal lobe epilepsy surgery during the past two decades" 86 : 224-227, 2009

33 Schurz H, "Evaluating the accuracy of imputation methods in a five-way admixed population" 10 : 34-, 2019

34 Fluss R, "Estimation of the Youden Index and its associated cutoffpoint" 47 : 458-472, 2005

35 Wang J, "Epilepsy-associated genes" 44 : 11-20, 2017

36 McCagh J, "Epilepsy, psychosocial and cognitive functioning" 86 : 1-14, 2009

37 Benbadis SR, "Epilepsy surgery, delays and referral patterns-are all your epilepsy patients controlled?" 12 : 167-170, 2003

38 Ramantani G, "Epilepsy surgery in children and adolescents" 1 : E86-E97, 2017

39 Bjellvi J, "Epilepsy duration and seizure outcome in epilepsy surgery : a systematic review and meta-analysis" 93 : e159-e166, 2019

40 Engel J Jr, "Early surgical therapy for drug-resistant temporal lobe epilepsy : a randomized trial" 307 : 922-930, 2012

41 Kwan P, "Early identification of refractory epilepsy" 342 : 314-319, 2000

42 Pelliccia V, "Early and late epilepsy surgery in focal epilepsies associated with long-term epilepsy-associated tumors" 127 : 1147-1152, 2017

43 Tang F, "Drug-resistant epilepsy : multiple hypotheses, few answers" 8 : 301-, 2017

44 Kwan P, "Drug-resistant epilepsy" 365 : 919-926, 2011

45 Kwan P, "Definition of drug resistant epilepsy : consensus proposal by the ad hoc Task Force of the ILAE Commission on therapeutic strategies" 51 : 1069-1077, 2010

46 Muller MP, "Can routine laboratory tests discriminate between severe acute respiratory syndrome and other causes of community-acquired pneumonia?" 40 : 1079-1086, 2005

47 Kim MK, "Association of restless legs syndrome variants in Korean patients with restless legs syndrome" 36 : 1787-1791, 2013

48 Hakimi AS, "A survey of neurologists’ views on epilepsy surgery and medically refractory epilepsy" 13 : 96-101, 2008

49 Wiebe S, "A randomized, controlled trial of surgery for temporal-lobe epilepsy" 345 : 311-318, 2001

50 Trinka E, "A definition and classification of status epilepticus--Report of the ILAE Task Force on classification of status epilepticus" 56 : 1515-1523, 2015